Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Strs Ohio

Strs Ohio trimmed its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 20.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 81,300 shares of the company’s stock after selling 20,700 shares during the period. Strs Ohio’s holdings in Hims & Hers Health were worth $723,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Custom Index Systems LLC acquired a new position in shares of Hims & Hers Health in the 4th quarter valued at approximately $132,000. Allspring Global Investments Holdings LLC raised its position in shares of Hims & Hers Health by 103.2% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 43,662 shares of the company’s stock valued at $389,000 after acquiring an additional 22,170 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Hims & Hers Health during the 4th quarter valued at approximately $48,000. Baldwin Brothers LLC MA raised its position in shares of Hims & Hers Health by 17.0% during the 4th quarter. Baldwin Brothers LLC MA now owns 22,128 shares of the company’s stock valued at $197,000 after acquiring an additional 3,215 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Hims & Hers Health by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock valued at $88,857,000 after acquiring an additional 428,671 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Soleil Boughton sold 2,503 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $15.65, for a total value of $39,171.95. Following the completion of the sale, the insider now owns 166,866 shares in the company, valued at $2,611,452.90. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider Soleil Boughton sold 2,503 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $15.65, for a total value of $39,171.95. Following the completion of the sale, the insider now owns 166,866 shares in the company, valued at $2,611,452.90. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Irene Becklund sold 2,747 shares of the company’s stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $12.08, for a total value of $33,183.76. Following the completion of the sale, the insider now owns 5,494 shares of the company’s stock, valued at approximately $66,367.52. The disclosure for this sale can be found here. Insiders sold a total of 548,150 shares of company stock worth $7,327,717 over the last 90 days. 31.63% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on HIMS. Imperial Capital raised Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price target on the stock in a research report on Wednesday, February 28th. Jefferies Financial Group reissued a “hold” rating and set a $15.00 price target (down from $17.00) on shares of Hims & Hers Health in a research report on Tuesday, April 16th. Truist Financial upped their price target on Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a research report on Tuesday, February 27th. Citigroup upped their price target on Hims & Hers Health from $12.00 to $16.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Finally, Tigress Financial upped their price objective on Hims & Hers Health from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, January 5th. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $14.85.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $12.27 on Friday. Hims & Hers Health, Inc. has a 1 year low of $5.65 and a 1 year high of $17.16. The stock has a market cap of $2.63 billion, a price-to-earnings ratio of -111.50 and a beta of 0.91. The business has a fifty day moving average of $13.70 and a 200-day moving average of $10.01.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03. The business had revenue of $246.60 million during the quarter, compared to analyst estimates of $245.84 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The company’s revenue was up 47.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.05) earnings per share. On average, equities research analysts predict that Hims & Hers Health, Inc. will post 0.1 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.